XTNT Form 4: Director awarded 158,228 deferred stock units

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a reported price of $0 per share. These DSUs will vest on November 15, 2026, provided the individual remains a director through that date. After vesting, the underlying shares will be settled at a later time according to the DSU award agreement. Following this grant, the director beneficially owns 158,228 shares in the form of DSUs under Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider JAIN ABHINAV

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	158,228	$0.00	--

Holdings After Transaction: Common Stock — 158,228 shares (Direct)

Footnotes (1)

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. Includes 158,228 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JAIN ABHINAV

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

373 INVERNESS PARKWAY, SUITE 206

(Street)

ENGLEWOOD CO 80112

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/15/2025		A		158,228(1)	A	$0	158,228(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 158,228 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

	/s/ Amy Culbert, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Xtant Medical Holdings (XTNT) disclose in this Form 4 filing?

Xtant Medical Holdings, Inc. disclosed that a director received a deferred stock unit award of 158,228 shares of common stock on November 15, 2025 under the company’s Amended and Restated 2023 Equity Incentive Plan.

How many Xtant Medical (XTNT) shares were granted to the director?

The director was granted 158,228 deferred stock units (DSUs), each representing a contingent right to receive one share of Xtant Medical Holdings, Inc. common stock.

When do the director’s deferred stock units (DSUs) vest at Xtant Medical (XTNT)?

The 158,228 DSUs will vest on November 15, 2026, conditioned on the reporting person remaining a director of Xtant Medical Holdings, Inc. through the vesting date.

What conditions apply to the Xtant Medical (XTNT) director’s DSU award?

The DSU award vests only if the individual remains a director through November 15, 2026, and settlement of the vested shares will occur later in accordance with the DSU award agreement.

What is the director’s beneficial ownership after this Xtant Medical (XTNT) transaction?

After the reported transaction, the director beneficially owns 158,228 shares of Xtant Medical Holdings, Inc. common stock in the form of deferred stock units, held as direct ownership.

Was there any cash consideration for the Xtant Medical (XTNT) DSU grant?

The Form 4 reports the transaction price as $0 per share for the grant of the 158,228 deferred stock units.